Caprock Group LLC Acquires New Holdings in Gilead Sciences, Inc. $GILD

Caprock Group LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 64,036 shares of the biopharmaceutical company’s stock, valued at approximately $7,234,000.

Other hedge funds have also modified their holdings of the company. Rothschild Investment LLC grew its position in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the last quarter. Hemington Wealth Management boosted its stake in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares in the last quarter. Ignite Planners LLC grew its holdings in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the last quarter. Archer Investment Corp increased its position in shares of Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its position in shares of Gilead Sciences by 0.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after purchasing an additional 87 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 2.9%

GILD stock opened at $147.23 on Wednesday. The company’s 50-day simple moving average is $128.39 and its 200-day simple moving average is $121.53. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $153.13. The firm has a market cap of $182.67 billion, a P/E ratio of 22.83, a PEG ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.99%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat estimates: Gilead reported $1.86 EPS vs. a $1.83 consensus and revenue rose ~4.7% YoY, helping demonstrate underlying portfolio resilience. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Dividend bump: Board raised the quarterly dividend by 3.8% to $0.82, supporting the stock’s income profile for yield‑focused investors. Gilead Sciences Announces 3.8% Dividend Increase
• Positive Sentiment: Pipeline and product momentum: Management cited growth in liver‑disease and HIV franchises and potential launches (including additional HIV options and two cancer therapy filings/approvals) and analysts remain upbeat on launches like Yeztugo. These could underpin medium‑term growth. WSJ: Gilead Profit Rises on Liver Disease, HIV Products Seeking Alpha: Q4 Preview
• Neutral Sentiment: Official earnings release and slide deck available for review — useful for digging into product-level trends and guidance assumptions. MarketWatch: Q4 and Full-Year Results
• Neutral Sentiment: Reported short‑interest data in filings is effectively meaningless/garbled for the period cited (shows 0 shares), so it provides no clear near‑term pressure signal.
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–$8.85 sits at the low end of Street forecasts and revenue guidance ($29.6–$30.0B) came in below consensus — the primary driver of the stock’s pullback as investors re‑price growth expectations. Benzinga: Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
• Negative Sentiment: Analyst/headline pushback: Several outlets flagged that the light outlook could weigh on the stock despite a clean beat, amplifying downward pressure in the session. Investor’s Business Daily: Light Outlook May Hurt Stock Reuters: Beat but Light Forecast
• Negative Sentiment: Insider selling: CEO disclosed a roughly $17.3M stock sale recently, which some investors view negatively even if driven by personal liquidity. AmericanBankingNews: CEO Stock Sale

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GILD. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. TD Cowen boosted their price target on Gilead Sciences from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.